The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated comprehensive cancer center located in Baltimore, Maryland.

During the past decade, Marlene & Stewart Greenebaum Cancer Center, University of Maryland conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Marlene & Stewart Greenebaum Cancer Center, University of Maryland" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 32 trials, followed by "University of Maryland, Baltimore" with 13 trials sponsored, "Children's Oncology Group" with 9 trials sponsored, "Radiation Therapy Oncology Group" with 7 trials sponsored and "Eastern Cooperative Oncology Group" with 7 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Marlene & Stewart Greenebaum Cancer Center, University of Maryland" #1 collaborator was "National Cancer Institute (NCI)" with 62 trials as a collaborator, "Cancer and Leukemia Group B" with 9 trials as a collaborator, "SWOG Cancer Research Network" with 7 trials as a collaborator, "Eastern Cooperative Oncology Group" with 6 trials as a collaborator and "University of Maryland Greenebaum Cancer Center" with 6 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Marlene & Stewart Greenebaum Cancer Center, University of Maryland" are "Leukemia" (23 trials), "Lymphoma" (19 trials), "Multiple Myeloma and Plasma Cell Neoplasm" (9 trials), "Lung Cancer" (8 trials) and "Prostate Cancer" (7 trials). Many other conditions were trialed in "Marlene & Stewart Greenebaum Cancer Center, University of Maryland" in a lesser frequency.

Most popular intervention types in "Marlene & Stewart Greenebaum Cancer Center, University of Maryland" are "Drug" (66 trials), "Biological" (32 trials), "Procedure" (24 trials), "Radiation" (20 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (21 trials), "etoposide" (17 trials), "filgrastim" (17 trials), "cisplatin" (13 trials) and "paclitaxel" (13 trials). Other intervention names were less common.

The vast majority of trials in "Marlene & Stewart Greenebaum Cancer Center, University of Maryland" are 71 trials for "All" genders, 7 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Marlene & Stewart Greenebaum Cancer Center, University of Maryland". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 75 completed trials in Marlene & Stewart Greenebaum Cancer Center, University of Maryland, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Marlene & Stewart Greenebaum Cancer Center, University of Maryland, 12 "Phase 1" clinical trials were conducted, 44 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".